Filiz Geyik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Filiz Geyik has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Beyhan Tüysüz
Department of Pediatric Genetics, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
3 shared publications - Gözde Yeşil
Department of Medical Genetics, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
2 shared publications - Nilay Güneş
Department of Pediatric Genetics, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey
2 shared publications - Tiraje Celkan
Department of Pediatric Hematology-Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye
2 shared publications - Aybike Sena Ozuynuk
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
1 shared publication - Aycan Fahri Erkan
Department of Cardiology, Faculty of Medicine, Ufuk University, Ankara, Turkey
1 shared publication
Latest Publications
- 28 December 2023
- Published by Istanbul University in Experimed
- Vol. 13 (3) , 281-289
Peroxisome Proliferator-activated Receptor-alpha (PPARA) and – Gamma (PPARG) Polymorphisms as Risk Factors for Dyslipidemia and MetS in Turkish Adults
- 28 December 2023
- Published by Istanbul University in Experimed
- Vol. 13 (3) , 281-289
Peroxisome Proliferator-activated Receptor-alpha (PPARA) and – Gamma (PPARG) Polymorphisms as Risk Factors for Dyslipidemia and MetS in Turkish Adults
- Open Access
- 12 October 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 13 (2) , 108-116
The Methylation Status in the Chromosome 11p15.5 Region and Metabolic Disorders in Children with Syndromic and Nonsyndromic Intrauterine Growth Restriction
Loss of methylation (LoM) of the imprinting control region 1 (ICR1) in the chromosome 11p15.5 domain is detected in patients with Silver-Russell syndrome (SRS), characterized by asymmetric pre- and postnatal growth restriction, and typical craniofacial features. The patients with intrauterine growth restriction (IUGR) possess a high risk for adult metabolic problems. This study is aimed to investigate the methylation levels of the chromosome 11p15.5 region and metabolic problems in children with syndromic and nonsyndromic IUGR. Methylation analysis was performed for chromosome 11p15.5 in 49 patients (33 with suspected SRS and 16 nonsyndromic IUGR) with Netchine-Harbison clinical scoring (NHCS); uniparental disomy for chromosomes 6, 7, 14, and 20 was evaluated for those who were negative. LoM of ICR1 was detected in 14 of 33 suspected SRS patients with 3 or more criteria of NHCS, 5 had borderline LoM. Maternal uniparental disomy of the chromosomes 7 and 14 was found in 2 patients. The overall detection rate of SRS was 45.5%. While clinical findings were similar in patients with LoM and borderline LoM of ICR1, typical craniofacial findings were significantly less in the patients with normal methylation. Methylation patterns were not found to be impaired in the nonsyndromic IUGR group. Metabolic complications were evaluated in a total of 63 patients including 33 SRS-suspicious, 16 nonsyndromic IUGR, and 14 patients with 3M or SHORT syndrome. Increased rates of hypercalciuria, insulin resistance, and dyslipidemia were detected in patients with both syndromic and nonsyndromic IUGR. We would like to emphasize that detecting typical facial findings is effective in the diagnosis of SRS and paying attention to metabolic problems in the follow-up of patients with IUGR is recommended.
- 12 October 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 13 (2) , 108-116
Open AccessThe Methylation Status in the Chromosome 11p15.5 Region and Metabolic Disorders in Children with Syndromic and Nonsyndromic Intrauterine Growth Restriction
Loss of methylation (LoM) of the imprinting control region 1 (ICR1) in the chromosome 11p15.5 domain is detected in patients with Silver-Russell syndrome (SRS), characterized by asymmetric pre- and postnatal growth restriction, and typical craniofacial features. The patients with intrauterine growth restriction (IUGR) possess a high risk for adult metabolic problems. This study is aimed to investigate the methylation levels of the chromosome 11p15.5 region and metabolic problems in children with syndromic and nonsyndromic IUGR. Methylation analysis was performed for chromosome 11p15.5 in 49 patients (33 with suspected SRS and 16 nonsyndromic IUGR) with Netchine-Harbison clinical scoring (NHCS); uniparental disomy for chromosomes 6, 7, 14, and 20 was evaluated for those who were negative. LoM of ICR1 was detected in 14 of 33 suspected SRS patients with 3 or more criteria of NHCS, 5 had borderline LoM. Maternal uniparental disomy of the chromosomes 7 and 14 was found in 2 patients. The overall detection rate of SRS was 45.5%. While clinical findings were similar in patients with LoM and borderline LoM of ICR1, typical craniofacial findings were significantly less in the patients with normal methylation. Methylation patterns were not found to be impaired in the nonsyndromic IUGR group. Metabolic complications were evaluated in a total of 63 patients including 33 SRS-suspicious, 16 nonsyndromic IUGR, and 14 patients with 3M or SHORT syndrome. Increased rates of hypercalciuria, insulin resistance, and dyslipidemia were detected in patients with both syndromic and nonsyndromic IUGR. We would like to emphasize that detecting typical facial findings is effective in the diagnosis of SRS and paying attention to metabolic problems in the follow-up of patients with IUGR is recommended.
- Open Access
- 13 September 2021
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 84 (4) , 472-481
THE RELATIONSHIP BETWEEN THE EXPRESSION LEVELS OF TISSUE INHIBITOR OF METALLOPROTEINASES-3 (TIMP3) AND SEVERITY OF ATHEROSCLEROSIS
- 13 September 2021
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 84 (4) , 472-481
Open AccessTHE RELATIONSHIP BETWEEN THE EXPRESSION LEVELS OF TISSUE INHIBITOR OF METALLOPROTEINASES-3 (TIMP3) AND SEVERITY OF ATHEROSCLEROSIS
- 20 April 2021
- Published by Wiley in Annals of Human Genetics
- Vol. 85 (5) , 155-165
Neurofibromatosis type 1: Expanded variant spectrum with multiplex ligation‐dependent probe amplification and genotype–phenotype correlation in 138 Turkish patients
Objective To investigate the variant spectrum and genotype–phenotype correlations in a Turkish cohort with Neurofibromatosis Type‐1 (NF1). Materials and methods We retrospectively investigated the clinical and molecular data of 138 NF1 patients from 129 families who had been followed‐up for a median of 3.9 (1.25–18.5) years. Results NF1 sequencing revealed 73 different intragenic variants, 19 of which were novel. Seven large deletions were detected by multiplex ligation‐dependent probe amplification (MLPA) analyses. The total detection rate of pathogenic NF1 variants was found to be 87.1%. Comparing age groups, cutaneous neurofibromas, freckling, and Lisch nodules were more prevalent in patients older than 12 years (p > .05). Optic glioma detected in 17.3% of the patients and was significantly more common before the age of 6 (p > .001). Other solid tumors developed in 5% of the patients. There was no genotype–phenotype correlation between patients with truncating and nontruncating variants. However, six out of seven patients with large deletions had significant developmental delay, one patient with the c.2970_2972delAAT (p.Met992del) variant had only typical pigmentary features, and another patient with the c.4267A > G (p.Lys1423Glu) variant had CALMs, freckling, neurofibromas, and Noonan‐like phenotype. Conclusions We described 19 novel variants and seven large deletions in NF1. Applying MLPA assay in NF1 is useful in expanding the molecular diagnosis. Although very limited genotype–phenotype correlation has been reported in NF1, the fact that specific phenotypic findings were observed in our patients with large deletions and two intragenic variants supports the studies published recently.
- 20 April 2021
- Published by Wiley in Annals of Human Genetics
- Vol. 85 (5) , 155-165
Neurofibromatosis type 1: Expanded variant spectrum with multiplex ligation‐dependent probe amplification and genotype–phenotype correlation in 138 Turkish patients
Objective To investigate the variant spectrum and genotype–phenotype correlations in a Turkish cohort with Neurofibromatosis Type‐1 (NF1). Materials and methods We retrospectively investigated the clinical and molecular data of 138 NF1 patients from 129 families who had been followed‐up for a median of 3.9 (1.25–18.5) years. Results NF1 sequencing revealed 73 different intragenic variants, 19 of which were novel. Seven large deletions were detected by multiplex ligation‐dependent probe amplification (MLPA) analyses. The total detection rate of pathogenic NF1 variants was found to be 87.1%. Comparing age groups, cutaneous neurofibromas, freckling, and Lisch nodules were more prevalent in patients older than 12 years (p > .05). Optic glioma detected in 17.3% of the patients and was significantly more common before the age of 6 (p > .001). Other solid tumors developed in 5% of the patients. There was no genotype–phenotype correlation between patients with truncating and nontruncating variants. However, six out of seven patients with large deletions had significant developmental delay, one patient with the c.2970_2972delAAT (p.Met992del) variant had only typical pigmentary features, and another patient with the c.4267A > G (p.Lys1423Glu) variant had CALMs, freckling, neurofibromas, and Noonan‐like phenotype. Conclusions We described 19 novel variants and seven large deletions in NF1. Applying MLPA assay in NF1 is useful in expanding the molecular diagnosis. Although very limited genotype–phenotype correlation has been reported in NF1, the fact that specific phenotypic findings were observed in our patients with large deletions and two intragenic variants supports the studies published recently.
- 11 March 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (6) , 1721-1731
Investigation of (epi)genotype causes and follow‐up manifestations in the patients with classical and atypical phenotype ofBeckwith‐Wiedemannspectrum
Beckwith‐Wiedemann syndrome (BWS) is a genomic imprinting disorder, characterized by macroglossia, abdominal wall defects, lateralized overgrowth, and predisposition to embryonal tumors. It is caused by the defect of imprinted genes on chromosome 11p15.5, regulated by imprinting control (IC) domains, IC1, and IC2. Rarely, CDKN1C and chromosomal changes can be detected. The aim of this study is to retrospectively evaluate 55 patients with BWS using the new diagnostic criteria developed by the BWS consensus, and to investigate (epi)genetic changes and follow‐up findings in classic and atypical phenotypes. Loss of methylation in IC2 region (IC2‐LoM), 11p15.5 paternal uniparental disomy (pUPD11), and methylation gain in IC1 region (IC1‐GoM) are detected in 31, eight, and five patients, respectively. Eleven patients have had no molecular defects. Thirty‐five patients are classified as classical and 20 as atypical phenotype. Patients with classical phenotype are more frequent in the IC2‐LoM (25/31), while patients with atypical phenotype are common in the pUPD11 group (5/8). Malignant tumors have developed in six patients (10.9%); three of these patients have IC1‐GoM, two pUPD11, one IC2‐LoM genotype, and four an atypical phenotype. We observed that the face was round in the infantile period and elongated as the child grew‐up, developing prognathism and becoming asymmetrical if hemi‐macroglossia was present in the classical phenotype. These findings were mild in the atypical phenotype. These results support the importance of using the new diagnostic criteria to facilitate the diagnosis of patients with atypical phenotype who have higher tumors risk. This study also provides important information about facial gestalt.
- 11 March 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (6) , 1721-1731
Investigation of (epi)genotype causes and follow‐up manifestations in the patients with classical and atypical phenotype ofBeckwith‐Wiedemannspectrum
Beckwith‐Wiedemann syndrome (BWS) is a genomic imprinting disorder, characterized by macroglossia, abdominal wall defects, lateralized overgrowth, and predisposition to embryonal tumors. It is caused by the defect of imprinted genes on chromosome 11p15.5, regulated by imprinting control (IC) domains, IC1, and IC2. Rarely, CDKN1C and chromosomal changes can be detected. The aim of this study is to retrospectively evaluate 55 patients with BWS using the new diagnostic criteria developed by the BWS consensus, and to investigate (epi)genetic changes and follow‐up findings in classic and atypical phenotypes. Loss of methylation in IC2 region (IC2‐LoM), 11p15.5 paternal uniparental disomy (pUPD11), and methylation gain in IC1 region (IC1‐GoM) are detected in 31, eight, and five patients, respectively. Eleven patients have had no molecular defects. Thirty‐five patients are classified as classical and 20 as atypical phenotype. Patients with classical phenotype are more frequent in the IC2‐LoM (25/31), while patients with atypical phenotype are common in the pUPD11 group (5/8). Malignant tumors have developed in six patients (10.9%); three of these patients have IC1‐GoM, two pUPD11, one IC2‐LoM genotype, and four an atypical phenotype. We observed that the face was round in the infantile period and elongated as the child grew‐up, developing prognathism and becoming asymmetrical if hemi‐macroglossia was present in the classical phenotype. These findings were mild in the atypical phenotype. These results support the importance of using the new diagnostic criteria to facilitate the diagnosis of patients with atypical phenotype who have higher tumors risk. This study also provides important information about facial gestalt.
- 1 December 2020
- Published by Elsevier in Atherosclerosis
- Vol. 315, e127
Association of itln1 gene polymorphism in coronary artery disease with type 2 diabetes
- 1 December 2020
- Published by Elsevier in Atherosclerosis
- Vol. 315, e127
Association of itln1 gene polymorphism in coronary artery disease with type 2 diabetes